Nordic Nanovector is a biopharmaceutical company dedicated to extending and improving the lives of patients with haematological cancers through the development and commercialisation of innovative targeted therapeutics. The company's lead clinical-stage product is Betalutin®, the first in a new class of antibody radionuclide conjugates (ARCs), designed to improve upon and complement current options for the treatment of non-Hodgkin lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities. Betalutin® is a tumour-seeking anti-CD37 antibody conjugated to a low-intensity radionuclide (lutetium-177). It is showing promising efficacy and tolerability in a Phase 1/2 clinical study in a difficult-to-treat NHL patient population. The company aims to develop Betalutin® for the treatment of patients with relapsed/refractory NHL. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. Nordic Nanovector is committed to building a pipeline of novel ARCs and antibody drug conjugates (ADCs) addressing multiple selected haematological malignancies based on proprietary technologies and expertise, and with technologies from partners where complementary.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company located in Hamilton, Ontario, Canada focused on becoming the leader in the targeted alpha therapy field. It is a spinout of the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production centre. Fusion’s deep radiochemistry expertise presents a technology platform that can be replicated to turn internalizing antibodies that have previously demonstrated limited clinical efficacy into highly effective cytotoxic drugs. Fusion’s ability to link the most effective isotopes to the targeting antibody allows for the creation of optimized agents for both diagnostic imaging and radioimmunotherapy (Precision Medicine). Following positive tumor identification with the imaging agent, treatment with the antibody linked to a therapeutic isotope delivers a cytotoxic payload into the cancer cell. Fusion’s lead product candidate, FPX-01, is a precision RIT that is a product of this innovative approach. FPX-01 has been designed to internalize into targeted cancer cells and deliver a lethal and highly localized radioactive payload. The precise targeting of this radiolabeled antibody causes selective and extremely effective cytotoxicity of tumor cells at relatively low doses of radioactivity.

TheraPharm GmbH operates as biotechnology company which engages in developing innovative diagnostic and therapeutic solutions. The company is headquartered in Baar, Switzerland.

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies for life threatening diseases using its alpha particle immunotherapy platform and other related technologies. The company’s principal product candidates include Actimab-A, a Phase I/II clinical trial monoclonal antibody for the treatment of acute myeloid leukemia in elderly patients; and Iomab-B that has completed a Phase I/II design trial used to condition the bone marrow of patients by destroying blood cancer cells in their bone marrow. It also offers BC8-Y-90 and BC8-SA product candidates, which are in physician sponsored clinical phase I trials at the Fred Hutchinson Cancer Research Center. The company was founded in 2000 and is based in New York, New York.

European Atomic Energy Community Euratom is a private company headquartered in Luxembourg, Luxembourg, that develops atomic energy.

Investment company that focuses on research and development businesses

Centre For Probe Development & Commercialization is a private company headquartered in Hamilton, ON, Canada. The firm develops, manufactures and distributes radiopharmaceuticals for early diagnosis and treatment of diseases. It was founded in 2008 by John Valliant. Bruno Paquin is currently the CEO of the company.\nThe company says this about itself: The Centre for Probe Development and Commercialization (CPDC) is a Centre of Excellence for Commercialization and Research (CECR) located at McMaster University in Hamilton, Ontario, Canada. CPDC is a private, not-for-profit company and global leader in the discovery, development and commercialization of next-generation radiopharmaceuticals that was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a pipeline of products along with a robust and reliable global supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer.

Akzo Nobel NV is a holding company, which engages in the manufacture and sale of coating and paint products. engages in the production and marketing of paints and coatings. It operates through the following segments: Decorative Paintings, Performance Paintings, and Corporate and Others. The Decorative Paints segment manufactures and supplies a range of interior and exterior decoration and protection products for professional and do-it-yourself markets. The Performance Coatings segment produces automotive and aerospace; industrial; marine and protective; and powder coatings. The company was founded in 1792 and is headquartered in Amsterdam, Netherlands.

The Korea Atomic Energy Research Institute (KAERI) in Daejeon, South Korea was established in 1959 as the sole professional research-oriented institute for nuclear power in South Korea, and has rapidly built a reputation for research and development in various fields. In 1995 KAERI designed and constructed the nation's first multipurpose research reactor, HANARO based on the Canadian MAPLE design. KAERI is dedicated to finding a wide range of uses for atomic energy. As examples, KAERI developed the world's first radiopharmaceutical "Milican injection" for treating liver cancer.

Korea Institute of Radiological & Medical Sciences specializes in radiation technology, research, development, genomics, and radiotherapy.

Oslo University Hospital (Norwegian: Oslo universitetssykehus) is a university hospital in Oslo, Norway. With over 24,000 employees it is the largest hospital in Northern Europe. It is affiliated with the Faculty of Medicine of the University of Oslo and is one of the largest medical research institutions in Europe. It was established in 2009, and is a result of the merger of the then-three university hospitals in Oslo.

National Research Council of Canada, provides research & development. It services include research programs and collaboration opportunities, technical and advisory services, licensing opportunities and industrial research assistance program. The company was founded by Graham W. Burton and is headquartered in Ottawa, ON.

OncoOne is a biotech start-up dedicated to developing innovative therapeutics to treat patients with solid tumors, founded by three individuals with a long history in drug development and oncology research from the pharmaceutical industry.

KaiBioTech Co., Ltd. engages in developing and manufacturing radiopharmaceuticals, dementia agents, and liver therapeutics. The company was founded on December 18, 2012 and is headquartered in Jeonju-si, South Korea.

Regents of The University of Michigan provides administers bonds on behalf of the University. The company is headquartered in Ann Arbor, MI.

Tri-Institutional Therapeutics Discovery Institute, Inc., part of Memorial Sloan Kettering Cancer Center, is an American company located in New York, NY, that operates scientific and medical institutions that works to more effectively develop therapeutics. It was founded by David A. Scheinberg.

AstraZeneca is an innovation-driven biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines that make a meaningful difference in healthcare. AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicines that are innovative, effective, and which offer added benefits such as reduced side effects or better ways of taking the treatment. AstraZeneca focuses on getting the best from every medicine they make by exploring all the ways it can be used or improved. AstraZeneca was established on April 6, 1999, in Cambridgeshire, United Kingdom.